Analysis for Stryker Corporation
Analysis summary
Stryker Corporation (SYK) currently has a total score of 55 points, placing it in the neutral range. The score is made up of Performance (58), Stability (66) and Trend (33). The profile is clearly uneven: Stability stands out while Trend lags.
Performance scores 58 points (neutral). Key strength: 10Y return at 285.8 %. Weaker metric: 1Y return at -4.6 %. This suggests stronger long-term than short-term performance.
Stability scores 66 points (strong). Best-ranked metric: max drawdown (3Y) at -16.8 %. Main drag: return/volatility ratio at -0.20. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 33 points (weak). Trend signals are mostly negative right now. Least weak signal: Price is about 3.3 % above SMA50. Main drag: trend strength at -0.42. That often means the move is strong, but not perfectly steady.
Overall, the picture is mixed: Stability does the heavy lifting while Trend holds the score back. On a metric level, max drawdown (3Y) stands out, while trend strength is the main weak spot.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Stryker Corporation fit best in FoxScore?
- Stryker Corporation fits a more defensive investor type in FoxScore: stability is the strongest part of the profile. That points to comparatively smaller drawdowns and calmer swings versus the universe — but prices can still fall.
- How meaningful is the available history for Stryker Corporation?
- Stryker Corporation currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.